logo
  

Coherus Reports Positive Results From Phase3 Toripalimab Trial On Esophageal Squamous Cell Carcinoma

Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences Inc. (CHRS) said an interim results from Phase 3 clinical trial has provided strong evidence that addition of toripalimab to chemotherapy as a first-line treatment for advanced or metastatic esophageal squamous cell carcinoma patients has superior progression free survival and overall survival than chemotherapy alone.

The company said it looks forward to updated analyses of overall survival of the JUPITER-06 study in the future. It believes that those results will build a strong argument to support the use of toripalimab in combination with chemotherapy as a new standard first-line treatment in patients with advanced or metastatic esophageal squamous cell carcinoma.

The pivotal study "JUPITER-06" (NCT03829969) is a randomized, double-blind, placebo-controlled Phase 3 clinical trial, which evaluates toripalimab in combination with chemotherapy as a first-line therapy for patients with advanced or metastatic esophageal squamous cell carcinoma. The study met the co-primary endpoints with statistically significant and clinically meaningful improvements in progression free survival and overall survival for patients treated with the toripalimab and chemotherapy combination compared to chemotherapy alone.

Junshi Biosciences and Coherus are planning in 2022 to submit a biologics license application supplement to the United States Food and Drug Adminstration for toripalimab for first-line treatment, in combination with platinum-based chemotherapy, of advanced or metastatic esophageal squamous cell carcinoma.

In China, the supplemental New Drug Application of the indication has been accepted by the National Medical Products Administration in July, 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lyons Magnus LLC has expanded its initial recall of nutritional and beverage products to include additional brands and code dates, the U.S. Food and Drug Administration announced. The products were recalled due to the potential for microbial contamination, including from the organisms Cronobacter sakazakii and Clostridium botulinum. Tesla Inc. founder and CEO Elon Musk has sold some of his stake in the luxury electric car maker to avoid an emergency sale of its stock in the event of a forceful Twitter deal. Twitter Inc. and Tesla shares were gaining more than 4 percent in the pre-market activity on the NYSE and Nasdaq, respectively, following the news. Meta Platforms Inc., the parent of Facebook, Instagram, and WhatsApp, has added three more new privacy features to WhatsApp in its bid to enhance control and privacy on the popular messaging app. These features will give the user more control over their messages with added interlocking layers of protection.
RELATED NEWS
Follow RTT